Gantenerumab - Roche

Drug Profile

Gantenerumab - Roche

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 05 Jun 2018 Hoffmann-La Roche initiates a phase III trial for Alzheimer's disease (Early-stage disease) in Spain, Denmark, Portugal and USA (SC) (NCT03443973)
  • 25 May 2018 Roche suspends patient enrolment in the phase II/III DIAN-TU trial for Alzheimer's disease (Early-stage disease) in USA, United Kingdom, Spain and Italy to explore options to improve the benefit / risk for these patients (PO)
  • 18 May 2018 Hoffmann-La Roche initiates a phase III trial for Alzheimer's Disease (Early-stage disease) in USA (SC) (NCT03444870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top